• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert Review of Molecular Diagnostics >Epigenetics of estrogen receptor-negative primary breast cancer
【24h】

Epigenetics of estrogen receptor-negative primary breast cancer

机译：雌激素受体阴性原发性乳腺癌的表观遗传学

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Increasingly, breast cancer is being recognized as a heterogeneous disease comprised of molecularly and phenotypically distinct intrinsic tumor subtypes with different clinical outcomes. This biological heterogeneity has significant implications, particularly as it relates to expression profiling of estrogen receptor (ER) status, as classifying breast cancers based on hormone receptor expression impacts not only prognosis but also treatment options and long-term outcomes. Epigenetics has emerged as a promising field for the assessment of hormone receptor status. Epigenetic aberrations have been shown to regulate ER and offer reversible targets for development of new therapies. This review covers ER-negative breast tumor epigenetic aberrations and summarizes the major epigenetic mechanisms governing ER expression and how it impacts treatment of ER-negative breast cancer.
机译：越来越多的乳腺癌被认为是一种异质性疾病，由分子和表型上不同的固有肿瘤亚型组成，具有不同的临床结果。这种生物异质性具有重要意义，尤其是因为它与雌激素受体（ER）状态的表达谱有关，因为根据激素受体表达对乳腺癌进行分类不仅会影响预后，还会影响治疗选择和长期结果。表观遗传学已成为评估激素受体状态的有前途的领域。表观遗传畸变已被证明可调节ER，并为开发新疗法提供可逆的靶标。这篇综述涵盖了ER阴性乳腺癌肿瘤的表观遗传畸变，并总结了控制ER表达的主要表观遗传机制及其如何影响ER阴性乳腺癌的治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号